A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors
Michael B Jameson, Danny Rischin, Mark Pegram, John Gutheil, Adam V Patterson, William A Denny, William R Wilson
Cancer Chemotherapy and Pharmacology | SPRINGER | Published : 2010
We thank the patients who participated in this trial and the research staff for their assistance in patient care and their dedication to clinical trials. We also thank Kashyap Patel and Prof. Nick Holford for advice on pharmacokinetic analysis, and Terri Melink for assistance with preparation of the manuscript. Financial support for this trial was provided by Proacta, Inc.